Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study

详细信息    查看全文

• 作者：Maria G. Kier^a ; ^b ; ^{maria.gry.gundgaard.kier@regionh.dk} ; Jakob Lauritsen^a ; Mette S. Mortensen^a ; Mikkel Bandak^a ; Klaus K. Andersen^c ; Merete K. Hansen^c ; Mads Agerbaek^d ; Niels V. Holm^e ; Susanne O. Dalton^b ; Christoffer Johansen^a ; ^b ; Gedske Daugaard^a
• 关键词：Bleomycin ; etoposide ; and cisplatin (BEP) ; Germ cell cancer ; Prognostic factors ; Survival
• 刊名：European Urology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：71
• 期：2
• 页码：290-298
• 全文大小：1484 K
• 卷排序：71

文摘

First-line treatment for patients with disseminated germ cell cancer (GCC) is bleomycin, etoposide, and cisplatin (BEP). A prognostic classification of patients receiving chemotherapy was published by the International Germ Cell Cancer Collaborative Group (IGCCCG) in 1997, but only a small proportion of the patients received BEP.ObjectiveTo estimate survival probabilities after BEP, evaluate the IGCCCG prognostic classification, and propose new prognostic factors for outcome.Design, setting, and participantsOf a Danish population-based cohort of GCC patients (1984–2007), 1889 received first-line BEP, with median follow-up of 15 yr. Covariates evaluated as prognostic factors were age, year of treatment, primary site, non-pulmonary visceral metastases, pulmonary metastases, and tumor markers.Outcome measurements and statistical analysisOutcomes measured were 5-yr progression-free survival (PFS), 5-yr disease-specific survival (DSS), and 5-yr overall survival (OS) as calculated using the Kaplan-Meier method and the Cox proportional hazards model.Results and limitationsThe 5-yr PFS, DSS, and OS were 87%, 95%, and 93%, respectively, for patients with seminomatous GCC (SGCC) and good prognosis. For nonseminomatous GCC (NSGCC) with good, intermediate, and poor prognosis, the 5-yr probabilities were 90%, 76%, and 55% for PFS; 97%, 87%, and 66% for DSS; and 95%, 85%, and 64% for OS, respectively. For SGCC patients, new adverse prognostic factors not included in the IGCCCG classification were higher age and lactate dehydrogenase ≥1.5 times the upper limit of normal. For NSGCC patients, higher age and pulmonary metastases were additional adverse prognostic factors. Treatment in earlier years was associated with higher mortality. Limitations include the small number of patients in the prognostic groups, and the inability to adjust for performance status and comorbidity.ConclusionsOur study reveals improved survival for disseminated GCC throughout the study period. We propose new prognostic factors for outcome for validation in larger cohorts of patients.Patient summaryIn this study of testicular cancer patients, we evaluated prognostic factors for outcome and calculated survival after standard chemotherapy. We find that survival has improved over the years and we propose new prognostic factors for outcome for validation in larger patient cohorts.